Table 2.
Associations between FGF-21 levels and participant demographics and disease characteristics at baseline
| Univariate Model | Multivariable Model (N=111) | |||
|---|---|---|---|---|
| β (95% CI) | p | β (95% CI) | p | |
| Age (per 1 yr) | 0.019 (0.004, 0.034) | 0.01 | 0.014 (0.0005, 0.028) | 0.04 |
| Female | 0.002 (−0.37, 0.38) | 0.99 | 0.13 (−0.21, 0.46) | 0.46 |
| Black or African American | −0.053 (−0.45, 0.34) | 0.79 | -- | -- |
| BMI (per 1 kg/m2) | 0.043 (0.019, 0.066) | 0.001 | -- | -- |
| ALMI Z-Score (per 1 unit) | 0.15 (−0.026, 0.33) | 0.09 | -- | -- |
| FMI Z-Score (per 1 unit) | 0.25 (0.10, 0.40) | 0.001 | -- | -- |
| Visceral Fat Area (per 1 cm) | 0.006 (0.004, 0.009) | <0.001 | 0.006 (0.004, 0.008) | <0.001 |
| Diabetes | −0.029 (−0.62, 0.56) | 0.92 | -- | -- |
| Cardiac Disease | 0.59 (0.23, 0.95) | 0.001 | -- | -- |
| EGFR (per 1 unit) | −0.008 (−0.015, −0.0006) | 0.03 | -- | -- |
| Current Smoker | 0.45 (0.011, 0.88) | 0.05 | 0.37 (−0.021, 0.75) | 0.06 |
| M-DAS (CRP) | 0.087 (−0.068, 0.24) | 0.27 | -- | -- |
| DAS-28 (CRP) | 0.083 (−0.073, 0.24) | 0.29 | -- | -- |
| MBDA Score | 0.005 (−0.008, 0.018) | 0.46 | -- | -- |
| vdHS Score | −0.0007 (−0.005, 0.003) | 0.72 | -- | -- |
| RA Duration (per 1 yr) | 0.013 (−0.004, 0.029) | 0.14 | -- | -- |
| Current Methotrexate | −0.35 (−0.74, 0.037) | 0.08 | −0.45 (−0.80, −0.10) | 0.01 |
| Current Biologic | 0.016 (−0.36, 0.39) | 0.93 | -- | -- |
| Current Prednisone | 0.052 (−0.32, 0.43) | 0.79 | -- | -- |
Legend: FMI Z-score, waist circumference, and visceral fat area are all highly collinear, and therefore only visceral fat area was included because it was the most correlated with FGF-21. All other variables that were moderately associated (p<0.2) with FGF-21 were initially tested in the multivariable model. Variables remaining moderately significant (p<0.10) in the multivariate model were included in the final model, along with basic demographic characteristics (age, gender).